Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Third Quarter Financial Results
Anavex Life Sciences to Participate at the BTIG Biotechnology Conference 2022
Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday, Aug. 9 2022
Long-lasting Effect of ANAVEX®3-71 Prevents Cognitive Decline in Animal Model of AD at AAIC 2022
Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release
Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022
Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Second Quarter Financial Results
Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tues. May 10, 2022
Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting
Anavex Life Sciences Invited to Present at a Neuro & Ophthalmology Conference
Anavex Life Sciences to Present at the Needham Virtual Healthcare Conference
Anavex Life Sciences to Participate in the Cantor Virtual Rare Orphan Disease Summit
Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from PDD study
Anavex Life Sciences to Participate in the Annual Needham Virtual Neuroscience Forum
Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP
Anavex Life Sciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 First Quarter Financial Results
Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71
Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
Follow us on social media
